Search Results

You are looking at 111 - 120 of 1,547 items for :

  • "characteristics" x
  • Refine by Access: All x
Clear All
Full access

EPR23-083: Non-Squamous, Metastatic Non–Small Cell Lung Cancer: Retrospective c-Met Overexpression Testing, Patient Characteristics, and Treatment Patterns

Mona H. Cai, Yookyung Christy Choi, Athan Vasilopoulos, Alexander Liede, Sidney S. Lindsey, Leon Raskin, Ethan Truong, Jeremy Fricke, Stephen B. Gruber, and Peter J. Ansell

-Met OE negative (NEG) were less likely to be Asian (14% vs 30%, respectively), more likely to be diagnosed with stage IV disease (57% vs 41%), and more likely to be PD-L1 POS (78% vs 41%). All other observed characteristics were similar between groups

Full access

HSR20-089: Association of Patient Clinico-Genomic Characteristics With Tumor Mutational Burden in Small Cell Lung Cancer: An Observational Study

Sumesh Kachroo, Changxia Shao, Kaushal Desai, Jinghua He, Fan Jin, and Shuvayu Sen

Background: This study evaluated the relationship between patients’ clinical and genomic characteristics and high tumor mutational burden (TMB) in the context of small cell lung cancer (SCLC). Methods: This was a retrospective cohort study using

Full access

Receipt of Screening Mammography by Insured Women Diagnosed With Breast Cancer and Impact on Outcomes

Marissa B. Lawson, Christoph I. Lee, Daniel S. Hippe, Shasank Chennupati, Catherine R. Fedorenko, Kathleen E. Malone, Scott D. Ramsey, and Janie M. Lee

addition, we used the following ICD codes to identify patients with screening encounters: Z12.31, V76.11, and V76.12. Statistical Analysis We compared clinical and tumor characteristics between women diagnosed with cancer who received screening

Full access

Disparities in the Use of Neoadjuvant Therapy for Resectable Pancreatic Ductal Adenocarcinoma

Jordan M. Cloyd, Chengli Shen, Heena Santry, John Bridges, Mary Dillhoff, Aslam Ejaz, Timothy M. Pawlik, and Allan Tsung

,500 Commission on Cancer–accredited facilities. Jointly sponsored by the American College of Surgeons and American Cancer Society, it currently captures more than 70% of newly diagnosed cancers within the United States. Relevant patient characteristics, tumor

Full access

Pancreatitis and Hyperlipasemia in the Setting of Immune Checkpoint Inhibitor Therapy

Matthew J. Townsend, Mofei Liu, Anita Giobbie-Hurder, Jordan S. Sack, Nicole R. LeBoeuf, F. Stephen Hodi, Julia McNabb-Baltar, and Shilpa Grover

≥2 of 3 criteria were met: (1) abdominal pain consistent with AP, (2) serum lipase ≥3 times the upper limit of normal (ULN), and (3) characteristic imaging findings. 11 Serum lipase, not amylase, was our primary laboratory marker, given its greater

Full access

Small Renal Masses With Tumor Size 0 to 2 cm: A SEER-Based Study and Validation of NCCN Guidelines

Angela Pecoraro, Giuseppe Rosiello, Stefano Luzzago, Marina Deuker, Franciska Stolzenbach, Zhe Tian, Shahrokh F. Shariat, Fred Saad, Alberto Briganti, Anil Kapoor, Cristian Fiori, Francesco Porpiglia, and Pierre I. Karakiewicz

data can provide further detail regarding the distribution of patient and renal cell carcinoma (RCC) characteristics within this special patient group. Based on these considerations, we reexamined patients with RCC with T1a 0- to 2-cm renal tumors to

Full access

Screening Process Failures for Hepatocellular Carcinoma

Amit G. Singal, Jorge A. Marrero, and Adam Yopp

characteristics could not be determined. Patients with Child-Pugh C cirrhosis and those with poor performance status were also excluded, because surveillance is not recommended in these patients. This study was approved by the Institutional Review Board at UT

Full access

Bone Metastases, Skeletal-Related Events, and Survival in Patients With Metastatic Non–Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors

Angel Qin, Songzhu Zhao, Abdul Miah, Lai Wei, Sandipkumar Patel, Andrew Johns, Madison Grogan, Erin M. Bertino, Kai He, Peter G. Shields, Gregory P. Kalemkerian, Shirish M. Gadgeel, Nithya Ramnath, Bryan J. Schneider, Khaled A. Hassan, Nicholas Szerlip, Zoey Chopra, Sara Journey, Jessica Waninger, Daniel Spakowicz, David P. Carbone, Carolyn J. Presley, Gregory A. Otterson, Michael D. Green, and Dwight H. Owen

approved by the Institutional Review Boards of both institutions. Patient demographics, disease characteristics (stage, histology, genomic alterations, metastatic burden [defined as the number of metastatic organ systems involved: 1, 2, ≥2]), treatment

Full access

National Quality Measure Compliance for Palliative Bone Radiation Among Patients With Metastatic Non–Small Cell Lung Cancer

Stephen R. Grant, Benjamin D. Smith, Lauren E. Colbert, Qunyh-Nhu Nguyen, James B. Yu, Steven H. Lin, and Aileen B. Chen

(1) assess the frequency of quality measure–concordant radiation for bone metastases as per NQF 1822; (2) describe variation in compliance by tumor, patient, and treatment characteristics; and (3) explore and consider the value, shortcomings, and

Full access

Factors Affecting Genetic Consultation in Adolescent and Young Adult Patients With Sarcoma

Grace E. McKay, Anna L. Zakas, Fauzia Osman, and Amanda Parkes

metastatic cancer at time of diagnosis, receipt of chemotherapy, and documentation of a genetics discussion with an oncology provider. Statistical Analysis Patient characteristics were recorded as percentages for categorical variables and as means and